Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer: Drug Slows Breast Cancer Progression

By Drug Discovery Trends Editor | December 5, 2012

Pfizer Inc. says that an experimental breast cancer drug it is developing was more effective than an older therapy at slowing the progression of advanced breast cancer.

The experimental treatment is designated PD-0332991. Pfizer says patients who took PD-0332991 and an older drug, letrozole, had progression-free survival of 26.1 months on average.

That means they lived about two years and two months before they died from their cancer or their disease began to progress again. Patients who were treated with letrozole alone had progression-free survival of 7.5 months on average.

Patients in the mid-stage trial had gone through menopause. They were all diagnosed with hormone receptor positive breast cancer lacking the protein HER2. Pfizer says about 60 percent of breast cancers fit that description. The company plans to start a late-stage trial of PD-0332991 and letrozole in post-menopausal women in 2013.

Pfizer will report more data from the study at a future medical conference. The New York drugmaker is also testing PD-0332991 as a treatment for other types of cancer.

Letrozole is a pill sold by Novartis AG under the brand name Femara. Generic versions are also available.

Release Date: December 5, 2012
Source: The Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE